MetaCap

Stoke Therapeutics Inc. (STOK)

NASDAQ: STOKHealth CareBiotechnology: Pharmaceutical PreparationsUSD

26.81-0.12 (-0.45%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

STOK stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$3.81
52-week range
22.05 – 40.22
Day range
25.94 – 27.78
Volume / Avg
615.75K / 1.02M
Beta
—

52-week range

$22.05$40.22

STOK stock today

Shares of Stoke Therapeutics (STOK) finished lower on Nov 20 at $26.81, a drop of 0.45% or $0.12 per share, versus the S&P 500's 3.70% decline. Shares are 33.3% below their 52-week high of $40.22, set on Mar 10, 2026 and 21.6% above the 52-week low of $22.05, in the middle of the past year's range. STOK is down 15.5% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 8.6%.

Stoke Therapeutics has posted a net loss over the last twelve months (EPS of -$3.81), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Stoke Therapeutics

Company profile

Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Ian F. Smith A.C.A., C.P.A.
Headquarters
Bedford, MA
Employees
170
IPO year
2019

Financial highlights

Full financials

In fiscal 2025, Stoke Therapeutics generated $184.4 million in revenue, up 404.5% from fiscal 2024, its 2nd consecutive year of revenue growth. Stoke Therapeutics reported a net loss of $6.9 million, compared with a loss of $89.0 million a year earlier. Operating margin was -11.2%.

Stoke Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$184.42M$36.55M$8.78M$12.40M—
Growth+404.50%+316.34%-29.22%——
Net income$-6.88M$-88.98M$-104.70M$-101.07M$-85.81M
EPS (diluted)$-0.12$-1.65$-2.38$-2.60$-2.34

Analyst forecast

Forecast

Consensus (14 analysts)

strong_buy

Avg. price target

$46.38+73.00%

  • Strong buy 2
  • Buy 12
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $35.00High $60.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Oct 29, 2026
EPS actual vs est.
$-0.65 vs $-0.88
Surprise
+26.14%

STOK news

All STOK news

Stoke Therapeutics peers

Health Care sector
STOK peer companies
CompanyPrice% ChgMarket capCompare
ETONEton Pharmaceuticals Inc.60.85-0.83%$1.76Bvs STOK
TRAXFirst Tracks Biotherapeutics Inc.41.64-6.34%$1.75Bvs STOK
SDGRSchrodinger Inc.22.93-12.95%$1.72Bvs STOK
ZYMEZymeworks Inc.26.14-2.68%$1.81Bvs STOK
KRSAKorsana Biosciences Inc.37.56+5.95%$1.71Bvs STOK
MRVIMaravai LifeSciences Holdings Inc. Class A6.98-2.92%$1.81Bvs STOK
SEPNSepterna Inc.38.61-1.51%$1.84Bvs STOK
VERAVera Therapeutics Inc. Class A25.45-4.86%$1.84Bvs STOK

Indexes, lists and sector

Stoke Therapeutics stock FAQ

What is Stoke Therapeutics's stock price today?

STOK last traded at $26.81 as of Nov 20, 4:00 PM EST, down 0.45% on the day. Prices are delayed at least 15 minutes.

Who is Stoke Therapeutics's CEO?

Mr. Ian F. Smith A.C.A., C.P.A. is the chief executive officer of Stoke Therapeutics Inc., which has about 170 employees.

What is the STOK 52-week high?

The 52-week high for STOK is $40.22 and the 52-week low is $22.05. The stock is currently 33.3% below its high.

Compare STOK